Stay updated with breaking news from Long Term Effectiveness. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This late-breaking data featured at RAD 2024 highlights several improvements in patient reported outcomes observed among atopic dermatitis patients, including itch relief.
P2Y12 inhibitor therapy in patients receiving aspirin therapy for ASCVD prevention does not affect the effectiveness of the aspirin therapy.
Findings seen for secondary prevention among patients with cardiovascular disease
There is no significant difference in the primary effectiveness or safety between enteric-coated aspirin and uncoated aspirin among patients with cardiovascular disease.
There is no decrease in efficacy but no significant benefit of enteric-coated aspirin over uncoated aspirin in patients with cardiovascular disease, post hoc results of the ADAPTABLE trial suggest.